CorePlus PR and its CEO, Mariano de Socarraz, had the opportunity to present the transformation process towards precision pathology that began in 2020 in their laboratories during the Health Industry Summit 2024 by the Puerto Rico Manufacturers Association and its distinguished panel of experts in “Health Care AI.” CorePlus’s mission in demonstrating the clinical utility of prostate cancer detection is clear: to advance the use of these technologies for the benefit of their patients and physicians.
“We are applying this technology every day in all our cases. We are part of a transformation, as instead of being a quality control tool, we now put it forward, and it is already telling the pathologist whether that case is positive or negative. The negative predictive value is almost 99.6%, so the most important thing is to eliminate what are called false negatives,” de Socarraz pointed out in a review published in the country’s media.
To access the article, click here: https://bit.ly/3wstTBY
